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FK 506 Dosage In Human Organ Transplantation 
A.B. Jain, J.J. Fung, R. Venkataramanan, S. Todo, M. Alessiani. and T.E. Starzl 
c~RMS has proved to be a new potent immunosuppres-
sive drug in the initial clinical trials. which began at 
the University Hospital in Pittsburgh in February 1989. 1 
FK 506 has been used as either primary immunosuppres-
sant for liver, kidney. heart, lung, and heartllung trans-
plants, or as rescue therapy for liver or kidney transplants. 
FK 506 is a macrolide derived from Streptomyces Isiiku-
baensis. FK 506 suppresses T -cell-mediated immunity by 
suppressing interleukin-2 synthesis in T cens.2 
The optima! dose of FK 506 in animals to achieve 
immunosuppression varies from 1-2 mgIkg in rats to 12-18 
mg in baboons, showing a difference among species.' 
The aim of this study was to look at the amount of FK 
506 used in human organ transplantation and the current 
maintenance doses of FK 506 and steroids in these pa-
tients. 
MATERIALS AND METHODS 
All of the patients at the University Hospital of Pittsburgh who 
received FK 506 as immunosuppression from February 28 to 
October 16, 1989, were included in the study. The details of FK 
506 rescue and primary immunosuppression lI.re given elsewher:e 
in this symposium. . 
There were 17 patients enrolled in FK ~MS trials from February 
to August 1989. An additional 46 patients were entered in Sep-
tember and another 48 patients were entered by October 16, 1989; 
a total of III patients were given FK 506 (Ytg 1). 'This number 
includes 6 children (9 months to 13 years of age) . One hundred t~o 
liver transplants, 9 kidney transplants, S pancreatic transplants, 3 
heart transplants, and 2 double lung transplan!S are inciuded. Ten 
patients received more than one allograft (4 kidneylliver, 4 pan-
creasl1iver, I pancreaslliverlkidney, and I lunilliver). 
All ~fthe patients were monitored with ~~ments oftrough 
plasma level of Ff<. 506.4 ,5 Of the II J patients treated with FK 506, 
11 patients were removed from thera~yK ~ighf patients died and 3 
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started on FK 506. . 
patients had the FK 506 stopped because of aDograft nephrec-
tomy. Thus, a total of 100 patients were available to study the 
maintenance dose of FK S()(j and steroids. 
Dosage 
The initial dosage schedule is shown in Table 1. FK 506 was given 
as a single intravenous dose (0.15 m&'kg) over 1-2 hours on the 
first day. On the second and third days, intravenous FK 506 was 
given at 0.075 mglkg at 12-hour intervals. The oral dose com-
menced on the fourth day (or later if the patient was not able to 
tolerate oral intake) at 0.15 ms'kg twice a day. In general, there 
was often an overlap period of intravenous and oral doses for 
12-36 hours. 
RESULTS 
Changes in FK 506 Dosing 
Adjustments of the oral FK 506 dose were made in each 
patient according to the response of graft function, patient 
tolerance of the drug, side effects of immunosuppression, 
and plasma trough levels of FK 506. During the adjustment 
period, the oral dose was doubled in 7 patients for 1-3 
weeks. In the other 93 patients, the dose was either 
reduced or maintained. . 
In 3 patients, it was decided to commence with oral 
doses ofFK 506 without intravenous FK 506 therapy. In 4 
patients, including 2 childr~nI intravenous therapy was 
discontinued after 2-3 dQses. 
The present maintenance doses of FK 506 are based on 
0.15 mglkg given at varying intervats. Thirty-five patients 
(35%! received the FK 506 dose twice a day, 49 patients 
(49%) received FK 506 once a day, 11 patients (11%) 
received FK 506 every other day, 4 patients (4%) received 
Table 1. Initial Dosage of FK 506 In All Patients 
Dosage Frequency 
Days Routa (rT1\Yk(I) (Per Day) 
1 IV 0.15 1 
2 and 3 IV 0.075 2 
4 and 5 Oral 0.15 2 
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Table 2. Present Maintenance Dose of FK 506 of 0.15 rngIkg 
Pal5enIs (%) 
35(35) 
.49(49) 
11 (11) 
4(4) 
1 (1)" 
12 
24 
48 
72 
168 
the dose every third day, and 1 patient (1%) remained on a 
FK 506 dose once a week (Table 2). 
Concomitant Use of Other Immunosuppressive Ag~nts 
Cy A was cqntinued in the first 14 FK 506 rescue patients, 
ofteil at reduced doses, up to 3 days in 5 patients and up to 
10 daYs in an additional 5 patients; it was discontinued in 
all the patients by the 12th dayIKe~cept in one" patient in 
whom iow-dose" CyA waS col1tin~ed for 7 weeks. In 
subsequent c~ 506 rescue patients, Cy A was discontinued 
before commencing FK 506 because of increases in daily 
trough levels of whole blood CyA, resulting in elevations 
of serum creatinine.6 " 
Azathioprine was discontinued in all patients receiving it 
prioi to FK 506 conversion. In 2 patients given FK 506 as 
primary immunosuppression, azathlopriile was added for 
refractory rejection. Steroid" doses were "continued for the 
first 5 days, then reduced depending of! the response in the 
resc~ group. In the primary transplant group, 1 g of 
methylprednisolone waS given intravenously on revascu-
larization of the graft: 200 mg o~ the first day, with a daily 
4O-mg reduction until the fifth day. A 20-mg/d dose was 
maintained. Subsequent doses of steroids were reduced in 
the primary group according to graft function and the 
overall clinical situation. Patients with lung allografts were 
not given steroids postoperatively. " 
The present maintenance" dose of steroids is 20 mg 
prednisone/d in 6 patients, 15 mgld in 3 patients, 10 mg/d in 
39 patients, and 5 mgld in 36 patients." Sixteen patients 
have been maintained without any steroids (Table 3). " 
FK Levels 
The daily plasma trough levels of FK 506 were determined 
in the first 65 patients given maintenance oral doses of FK 
Table 3. Present Maintenance Dose of Prednisone 
Palenls (%I Dose (mgld) 
6 (6) 
3 (3) 
39 (39) 
36(36) 
16 (16) 
20 
15 
10 
5 
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Table 4. Plasma FK 506 Trough LlWeis (nglmQ WIth Oral Dose 
·(N=382)·· 
Level 
% 
<1 
65 
1·2 
18 
2-4 
8 
4-6 
4 
>6 
5 
506 A total of 382" ~bserv~tio~s in the 6S pati~nts are s~arized in Table 4. Sixty·five percent of these FK 506 
trough levels ~ere <1 ng/mI, while 83% of such determi-
nations were <2 ng/ml." . 
DISCUSSION 
As with any new drug. dosage can be difficult to deter-
nune. This is especially true for immunosuppressive 
agents. ~use with over-dosage the~ i~ a risk of infec-
tion, drug toxicity, and even the developme~ of neo-
plasms·. With underdosage, rejection could occur. . 
A dose of 0.15 mgllcgld was initially 'chosen to stu~y the 
safety "profile and to o\:!tain pharmacokinetic profiles. This 
was found" to be a· therapeutic dose in humans. The 
req4irement for maintrlniDg FK ~MS immunosuppression is 
flexible.' Some patients appear to be adequately imnlUno-
suppressed with half of the initial oral FK 506 dose or less. 
Routine use of" aza~hioprine is not necessary and use of 
Cy A should be avoided. 
The maintenance' dose of steroids was low. Since the 
majority of FK 506 patients have been followed fOF a short 
period, it is probable that the requirement of steroids can 
be smaller still. At present, over 52% of patients are either 
receiving no steroids or only 5 mg of pr~dnisone daily; only 
9% of patients are taking more than 10 mg/d of prednisone. 
In Conclusion, relatively low maintenance doses of FK 
506, aJong with low doses of steroids, are adequate to 
achieve immunosuppression in human organ transplanta-
tion. Concomitant use of azathioprine is not necessary in 
our experience, and simultaneous use of CyA should be 
avoided. 
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